We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+54.28%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$342M
AUM Growth
+$109M
Cap. Flow
+$26.1M
Cap. Flow %
7.65%
Top 10 Hldgs %
88.53%
Holding
22
New
3
Increased
1
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$29.9M
2
AXSM icon
Axsome Therapeutics
AXSM
+$5.31M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$2.42M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$188K

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$4.03M
2
DBVT
DBV Technologies
DBVT
+$3.89M
3
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$2.05M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$1.49M
5
KA
Kineta, Inc. Common Stock
KA
+$259K

Sector Composition

Rank Sector Weight
1 Healthcare 98.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$17.1B
$59.3M 17.37%
504,210
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$58.6M 17.14%
1,138,075
– –
TCDA
3
DELISTED
Tricida, Inc. Common Stock
TCDA
$37.2M 10.88%
962,695
-1
-0% -$23
SWAV
4
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$30.2M 8.83%
+901,256
New +$29.9M
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$28.8M 8.43%
2,252,460
– –
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2.36B
$26.4M 7.74%
3,249,164
– –
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$19.9M 5.83%
362,010
– –
KALV
8
DELISTED
KalVista Pharmaceuticals
KALV
$16.4M 4.8%
573,482
-185,699
-24% -$4.03M
RARX
9
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$14.2M 4.15%
632,480
– –
KNSA icon
10
Kiniksa Pharmaceuticals
KNSA
$4.92B
$11.5M 3.38%
639,230
– –
CNST
11
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$9.85M 2.88%
726,677
– –
AXSM icon
12
Axsome Therapeutics
AXSM
$11.8B
$8.14M 2.38%
+571,956
New +$5.31M
SPRO icon
13
Spero Therapeutics
SPRO
$91.5M
$6.07M 1.78%
474,015
– –
PTGX icon
14
Protagonist Therapeutics
PTGX
$9.06B
$3.41M 1%
271,377
+21,353
+9% +$188K
MRNS
15
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.11M 0.91%
185,969
– –
BLPH
16
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$2.71M 0.79%
276,625
– –
LJPC
17
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.39M 0.7%
+371,400
New +$2.42M
KDMN
18
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.17M 0.63%
820,123
-591,305
-42% -$1.49M
MTVA
19
MetaVia Inc
MTVA
$8.83M
$591K 0.17%
8
– –
KA
20
DELISTED
Kineta, Inc. Common Stock
KA
$538K 0.16%
3,051
-530
-15% -$259K
ORTX
21
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$221K 0.06%
1,238
-13,618
-92% -$2.05M
DBVT
22
DBV Technologies
DBVT
$870M
– –
-46,315
Closed -$3.89M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q1 2019 Portfolio in Review

As of Q1 2019, VHCP Management II held 22 positions worth $342M, up 47% from $233M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

VHCP Management II deployed $26.1M of net new capital in Q1 2019, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Shockwave Medical, Inc. Common Stock: 901,256 shares worth $30.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was KalVista Pharmaceuticals, an estimated $4.03M trimmed.

  • VHCP Management II's largest Q1 2019 buy was Shockwave Medical, Inc. Common Stock: 901,256 shares worth $30.2M.
  • VHCP Management II added most to Protagonist Therapeutics in Q1 2019, an estimated $188K increase.
  • VHCP Management II's biggest Q1 2019 reduction was KalVista Pharmaceuticals, cutting an estimated $4.03M.
  • VHCP Management II fully exited DBV Technologies in Q1 2019, selling an estimated $3.89M.
  • VHCP Management II's ten largest holdings make up 89% of its $342M portfolio in Q1 2019.
  • VHCP Management II opened 3 new positions and closed 1 in Q1 2019.
  • VHCP Management II's portfolio value rose 47% quarter-over-quarter to $342M.

Based on VHCP Management II's 13F filing for Q1 2019, filed 14 May 2019.